Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Llopiz, D. (Diana) | - |
dc.creator | Dotor, J. (Javier) | - |
dc.creator | Casares, N. (Noelia) | - |
dc.creator | Bezunartea, J. (Jaione) | - |
dc.creator | Diaz-Valdes, N. (Nancy) | - |
dc.creator | Ruiz, M. (Marta) | - |
dc.creator | Aranda, F. (Fernando) | - |
dc.creator | Berraondo, P. (Pedro) | - |
dc.creator | Prieto, J. (Jesús) | - |
dc.creator | Lasarte, J.J. (Juan José) | - |
dc.creator | Borras-Cuesta, F. (Francisco) | - |
dc.creator | Sarobe, P. (Pablo) | - |
dc.date.accessioned | 2012-01-15T14:59:11Z | - |
dc.date.available | 2012-01-15T14:59:11Z | - |
dc.date.issued | 2009 | - |
dc.identifier.citation | Llopiz D, Dotor J, Casares N, Bezunartea J, Diaz-Valdes N, Ruiz M, et al. Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy. Int J Cancer 2009 Dec 1;125(11):2614-2623. | es_ES |
dc.identifier.issn | 0020-7136 | - |
dc.identifier.uri | https://hdl.handle.net/10171/20419 | - |
dc.description.abstract | Transforming growth factor-beta (TGF-beta) is a cytokine with potent immunosuppressive effects and is overexpressed in many tumors. Therefore, development of molecules able to inhibit TGF-beta is of paramount importance to improve the efficacy of antitumor immunotherapy. TGF-beta inhibitor peptides P144 and P17 were combined with the administration of adjuvant molecules poly(I:C) and agonistic anti-CD40 antibodies, and their effect on the growth of E.G7-OVA established tumors and on antitumor immune response was evaluated. Tumor rejection efficacy of a single administration of adjuvants was enhanced from 15 to 70 % when combined with repeated injections of TGF-beta inhibitor peptides. Simultaneous administration of adjuvants and TGF-beta inhibitor peptides was required for maximal therapeutic efficacy. Although tumor cells produced TGF-beta, it was found that the beneficial effect of peptide administration was mainly due to the inhibition of TGF-beta produced by regulatory CD4(+)CD25(+) T cells rather than by tumor cells. The enhanced antitumor effect was accompanied by a higher activity of dendritic cells, natural killer cells and tumor antigen-specific T cells, as well as by a decrease in the number of myeloid-derived suppressor cells. In conclusion, administration of peptide inhibitors of TGF-beta in therapeutic vaccination enhances the efficacy of immunotherapy by increasing antitumor immune responses. These peptide inhibitors may have important applications for current immunotherapeutic strategies. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley blackwell | es_ES |
dc.rights | info:eu-repo/semantics/closedAccess | - |
dc.subject | Regulatory T cells | es_ES |
dc.subject | TGF-β | es_ES |
dc.subject | Inhibitor peptides | es_ES |
dc.subject | Tumor immunotherapy | es_ES |
dc.title | Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.type.driver | info:eu-repo/semantics/article | es_ES |
dc.identifier.doi | http://dx.doi.org/10.1002/ijc.24656 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.